Translational Disruption of NRF2 By Zotatifin Enhances Sensitivity to Ferroptosis and CAR-T Cells in Diffuse Large B-Cell Lymphoma (ASH 2024) - Nov 6, 2024 - Abstract #4167; Pres time: Dec 9, 2024; 06:00 PM - 08:00 PM; Location: Halls G-H (San Diego Convention Center); "We observed strong synergy, however, between zotatifin and various ferroptosis inducers, including erastin, RSL3, dimethyl formamide (DMF), sulfasalazine (SASP), ML385, and the pharmacokinetically optimized compound imidazole ketone erastin (IKE), while the anti-ferroptotic antioxidant N-acetyl cysteine (NAC) was antagonistic. These results advocate for clinical strategies to enhance investigational ferroptosis inducers and approved CAR-T cells. Further optimization of these regimens holds potential to enhance therapeutic efficacy and overcome resistance mechanisms in DLBCL treatment."
CAR T-Cell Therapy • IO biomarker • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • EIF4A1 • EIF4A2 • IFNG • NFE2L2 • SLC3A2
|
|
Paola Manara, MS1; Venu Venkatarame Gowda Saralamma, PhD2; Austin Daniel Newsam, BS1; Marco Vincenzo Russo, PhD3; Tyler Andrew Cunningham, PhD4; Alicia Bilbao Martinez, BS3; Nikolai Fattakhov, PhD3; Kyle Hoffman, PhD5; Alexandra Marie Carbone, BS1; Abdessamad Youssfi Alaoui, PhD2; Dhanvantri Chahar, PhD2; Olivia Barbara Lightfuss, BS1; Francesco Maura, MD6; Daniel Bilbao, PhD3; Jonathan H. Schatz, MD2
|